Linsitinib is an experimental small-molecule inhibitor targeting the insulin-like growth factor-1 receptor (IGF-1R) and the insulin receptor, investigated for its potential to treat various solid tumors… Read more
Linsitinib is an experimental small-molecule inhibitor targeting the insulin-like growth factor-1 receptor (IGF-1R) and the insulin receptor, investigated for its potential to treat various solid tumors by inhibiting cell proliferation and inducing apoptosis. Pharmaceutical laboratories utilize high-quality Linsitinib reference standards to support rigorous quality control processes and analytical method validation during drug development. For complex bioanalytical applications, Linsitinib-13C6 provides a reliable stable isotope labelled compound, functioning as an internal standard in liquid chromatography-tandem mass spectrometry (LC-MS/MS) to ensure precise quantification of the drug and its related substances in biological matrices. These reference materials are essential for accurate impurity profiling and pharmacokinetic studies, ensuring that experimental methods meet the strict regulatory requirements necessary for evaluating this kinase inhibitor’s therapeutic efficacy.